drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Autologous CD19-directed CAR T-cell therapy. Patient T cells are modified to express a CAR with CD3ζ and costimulatory domains; upon binding CD19 on malignant B cells, they activate, expand, and kill targets via perforin/granzyme pathways, leading to depletion of CD19+ cells and B-cell aplasia. Given by intravenous autotransfusion for relapsed/refractory CD19+ B-ALL/B-lymphoblastic lymphoma.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Immunotherapy, Adoptive
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a CD19-specific chimeric antigen receptor (CAR) containing CD3ζ and costimulatory domains. Upon binding CD19 on malignant B cells, CAR signaling activates and expands the T cells, which mediate cytotoxicity via perforin/granzyme, leading to targeted elimination of CD19+ cells and on‑target B‑cell aplasia.
drug_name
BIC-2019
nct_id_drug_ref
NCT06355739